

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SENATE

01 AUG 14 AM 10: 06

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Novartis			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address 701 Pennsylvania Ave. NW Suite 725 City Washington State/Zip (or Country) DC 20004			
3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____			
4. Contact Name Burt Rosen		Telephone 202-638-7429	E-mail (optional) _____
			5. Senate ID # 9204-12
7. Client Name <input type="checkbox"/> Self Novartis Corporation			6. House ID # 33589000

TYPE OF REPORT 8. Year 2001 Midyear (January 1-June 30) OR Year End (July 1-Dec

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report >> Termination Date _____

11. No Lobbying

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input type="checkbox"/> >> \$ _____ Income (nearest \$20,000)	EXPENSES relating to lobbying activities for this reporting period were: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$1,420,000.00</u> Expenses (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of <input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definition <input type="checkbox"/> Method B. Reporting amounts under section 6033 the Internal Revenue Code <input type="checkbox"/> Method C. Reporting amounts under section 162(c) Internal Revenue Code

Signature _____

Burt Rosen

Date _____

8-13-2001



Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific Lobbying issues
Appropriations: FDA
Appropriations: USDA

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bumbaugh, Deborah	
Drake, David	
Elkin, James	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Co: too Novartis AG, as its parent, will benefit.

Signature Burt Rosen Date 8-13-2001



Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

- 15. General issue area code CPT (one per page)
- 16. Specific Lobbying issues
**S.754/H.R.1063, Increasing Ability to Enforce Antitrust Laws,
S.812/H.R.1862, Greater Access to Affordable Pharmaceuticals Act,**

- 17. House(s) of Congress and Federal agencies contacted Check if None
**House of Representatives
Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Casserly, Dan	
Drake, David	
Elkin, James	

- 19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Co too Novartis AG, as its parent, will benefit

Signature Burt Rosen Date 8-13-2001



Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.**

15. General issue area code FOO (one per page)

16. Specific Lobbying issues
**National Uniformity for Food
Genetically Engineered Food Right to Know Act
Country of Origin Labeling
GMO Labeling**

17. House(s) of Congress and Federal agencies contacted Check if None

**Department of Agriculture
Environmental Protection Agency
Food & Drug Administration
House of Representatives
Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Drake, David	
Elkin, James	
Haller, Sarah	
King, Rachel	
Rosen, Burt	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Co too Novartis AG, as its parent, will benefit.

Signature Burt Rosen Date 8-13-2001



Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific Lobbying issues

- H.R. 1387, Drug Availability and Health Care Access Improvement Act of 2001,**
- H.R.1530, Prescription Drug Competition Act of 2001,**
- H.R.1624/S.913, Access to Cancer Therapies Act of 2001,**
- S. 1239 , Medicare Rx Drug Discount and Security Act of 2001,**
- S.10 , Medicare Prescription Drug Coverage Act of 2001,**
- S.1135, Medicare Reform Act of 2001,**
- S.1185 , Seniors Prescription Insurance Coverage Equity Act of 2001,**
- S.838 IS, Better Pharmaceuticals for Children Act ,**
- S.880/H.R.1839, Immunosuppressive Drug Coverage Act of 2001,**
- S.982 IS /H.R.2058 IH, Medicare Wellness Act of 2001,**

17. House(s) of Congress and Federal agencies contacted Check if None
Drug Enforcement Administration
Food & Drug Administration
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bumbaugh, Deborah	
Casserly, Dan	
Drake, David	
Elkin, James	
Haller, Sarah	
King, Rachel	
Rosen, Burt	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Co too Novartis AG, as its parent, will benefit.

Signature Burt Rosen Date 8-13-2001



Registrant Name: Novartis

Client Name: Novartis Corporation

Item	Description	Data
16	Lobbying Issues	Medicare Prescription Drugs Snowe/Wyden The Senior Prescription Insurance Coverage Equity Act (S.11 Breaux/Thomas Medicare Reform Plan Health Insurance Portability and Accessibility Act FDA Modernization Act Medical Records Privacy - Senators Jeffords, Bennett, Leahy, Kennedy Bills Prospective Payment System Gene Therapy Drug Reimportation Medicare Reform Agriculture Appropriations 2001 - Drug Reimportation Agriculture Appropriation 2001 (FDA funding) Stem Cell Research Pediatric Exclusivity Direct-to-Consumer Advertising PDUFA The Bipartisan Medicare Prescription Drug Act of 2001 (Sen. Kennedy-Draf President Bush's "Helping Hand" proposal



Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific Lobbying issues
H.R. 1530, Prescription Drug Competition Act of 2001,
H.R.1387, Drug Availability and Health Care Access Improvement Act of 2001,
HR1624/S913, Access to Cancer Therapies Act,
S. 10, Medicare Prescription Drug Coverage Act of 2001 ,
S.1135, Medicare Reform Act of 2001,
S.1185, Seniors Prescription Insurance Coverage Equity Act of 2001,
S.1239, Medicare Rx Drug Discount & Security Act of 2001,
S.880/H.R.1839, Immunosuppressive Drug Coverage Act of 2001,
S.982 IS/H.R. 2058 IH, Medicare Wellness Act of 2001,

17. House(s) of Congress and Federal agencies contacted Check if None
Department of Health & Human Services
Food & Drug Administration
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bumbaugh, Deborah	
Casserly, Dan	
Drake, David	
Elkin, James	
Haller, Sarah	
King, Rachel	
Rosen, Burt	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Co too Novartis AG, as its parent, will benefit.

Signature Burt Rosen Date 8-13-2001



Registrant Name: Novartis

Client Name: Novartis Corporation

Item	Description	Data
16	Lobbying Issues	Medicare Prescription Drug & Modernization Act The Bipartisan Medicare Prescription Drug Act of 2001 (Sen. Kennedy-Dra President Bush's "Helping Hand" proposal Prospective Payment System Medicare Reform



Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific Lobbying issues
R&D Tax Credit

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Drake, David	
Elkin, James	
Haller, Sarah	
King, Rachel	
Rosen, Burt	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Co. too Novartis AG, as its parent, will benefit.

Signature Burt Rosen Date 8-13-2001



Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TRD (one per page)

16. Specific Lobbying issues
Economic Sanctions
SRM Ban/BSE
China/World Trade Organization
Fast Track Negotiating Authority
Capital Market Sanctions

17. House(s) of Congress and Federal agencies contacted
Department of Commerce
Food & Drug Administration
House of Representatives
Senate

Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Haller, Sarah	
King, Rachel	
Rosen, Burt	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Co too Novartis AG, as its parent, will benefit.

Signature Burt Rosen Date 8-13-2001

